Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: J Pediatr Surg. 2018 Jun 9;54(3):543–549. doi: 10.1016/j.jpedsurg.2018.06.005

Table 1.

Inclusion criteria for IRB-approved ovarian tissue cryopreservation protocol.

General Criteria:

  • <30 years of age

  • Any health condition that requires removal of both ovaries

Oncology/Medical Therapies:
 Radiation Therapy

  • whole abdomen or pelvic irradiation

    • ≥10 Gy in post-pubertal girls

    • ≥15 Gy in prepubertal girls

  • cranial irradiation ≥30 Gy

  • total body irradiation

 Chemotherapy

  • alkylating-intensive chemotherapy

    • cyclophosphamide cumulative dose ≥7.5 g/m2

    • any treatment regimen containing procarbazine

    • busulfan cumulative dose >600 mg/m2

  • alkylating agent dose (AAD) score ≥3a

  • cyclophosphamide equivalent dose (CED) ≥ 4000 mg/m2b

 Stem Cell Transplant

  • conditioning regimen including alkylating agents/total body irradiation

a

Alkylating agent dose (AAD): a score of 1, 2, or 3 is given depending on the tertile the alkylating agent falls within.

b

Cyclophosphamide equivalent dose (CED): risk-stratification calculation according to dosages of alkylating agents received.